Under the Paperwork Reduction Act of 1995, no persons are required to r

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Application Number		10593686
Filing Date		2006-09-19
First Named Inventor Rober		rt James Paech
Art Unit		
Examiner Name		
Attorney Docket Number		11774-00002

				U.S.	PATENTS		Remove	
Examiner Initial*	Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Releva		Lines where les or Relevan
	1	6729682		2004-05-04	Noble			
	2	6077080		2000-06-20	Rai			
	3	5567159		1996-10-22	Tehan			
	4	5429513		1995-07-04	Diaz-Plaza			
	5	4655713		1987-04-07	Weiss			
If you wish	n to a	dd additional U.S. Paten			lease click the Add button.		Add	
			U.S.P	ATENT APPLI	CATION PUBLICATIONS		Remove	
Examiner Initial*	Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevan Figures Appear		
	1							
If you wiel	to a	ld additional LLS Public	had An	nlication citation	n information please click the Ad-	hutton	Add	

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

Examiner Cite Foreign Document Country

Application Number		10593686	
Filing Date		2006-09-19	
First Named Inventor Rober		rt James Paech	
Art Unit			
Examiner Name			
Attorney Docket Number		11774-00002	

Name of Patentee or

Applicant of cited

Pages.Columns.Lines

where Relevant

Initial.	No	Num	per ³	Code	Code	Date	Docum	ent	Figures Appear	
	1	W02	00167278	wo		2001-09-13	Baek			
	2	W02	004025603	wo		2004-03-25	Guffant			
	3	DE 11	0203746	DE		2004-02-19	Stembe	rg	Figures 1 and 2	
If you wis	h to a	dd add	itional Foreign P	atent Document	citation	information pl	ease di	k the Add buttor	Add	
				NON-PATER	NT LITE	RATURE DO	CUMEN	TS	Remove	
Examiner Initials*	Examiner Cite Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.				Ţ5					
	1	The N	Macquarie Dictional	ry, Second Revisio	on, 1988	, pages 21-27, a	and 43-46	i, The Macquarie L	.ibrary, Australia.	
If you wis	h to a	dd add	fitional non-paten	t literature docu	ment cit	tation informati	ion pleas	e click the Add I	outton Add	
				EX	AMINE	R SIGNATUR	E			
Examiner	Signa	ature					Da	e Considered		

Kind Publication

See Kint Code of USPTO Petert Documents at year USPTO_CODY or MPEP 90104. *Enter date that issued the document, by the two letter code (WPO) Standard ST3.) **Enter price papers perior thousands, the included on the year of the register or perior day precise the serial results of the peter document.

*Included Cocument by the appropriate symbols as andicated on the document under WPO Standard ST1.66 if possible. **Dapticant is to place a check mark here if English inauguage streatfactors is attached.**

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through a citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)

	Application Number		10593686		
	Filing Date		2006-09-19		
	First Named Inventor Rober		rt James Paech		
	Art Unit				
	Examiner Name				
Attorney Docket Number		ec	11774-00002		

CERTIFICATION STATEMENT

Please see 37	CFR 1.97	and 1.98 to make th	e appropriate selection(s):
---------------	----------	---------------------	-----------------------------

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. Sea 97 CFF 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office is a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquity, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 175(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 177(40).

- See attached certification statement.
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature.

_			
Signature	/Jamie T. Gallagher/	Date (YYYY-MM-DD)	2007-04-06
Name/Print	Jamie T. Gallagher	Registration Number	51714

This collection of information is required by 3T CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is for life railed by the USPTO to process) an application. Confidentiality is governed by \$5 U.S. C. 12.0 and 3T CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application from the USPTO. Time will vary depending upon the individual case: Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. operatment of Commence, P.O. 8bx 1445, Alexandrin, V.S. 2311-1450, D.O. NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. 8bx 1459, Alexandria, V.S. 2311-1450.

Privacy Act Statement

The Privacy Act of 1974 (P. L. 93-579) requires that you be given certain information in connection with your submission of the stackhold from related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, places be advised that (1) the general authority for the collection of this information is 35 U.S.C. 2(b)(2); (2) familishing of the information solicided is couldrain; and (3) the primoral pursuance for which the information is used by the U.S. Patient and Trademan Coffice is to process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested process and/or examine your submission related to a patient agricultant or patient. If you do not furnish the requested results of the patient of the patient and the patient of the patient

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement negotiation.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record pertains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974, as amended, pursuant to 5 U.S.C. 552(m).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uturing an insection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 4d U.S.C. 2904 and 2905. Such disclosure shall be made in accordance with the GSA requisions governing inseption of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make determinations about individuals.
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the
 application pursuant to 35 U.S.C. 12(2) or issuance of a patent pursuant to 35 U.S.C. 151. Further, a record may be
 disclosed, subject to the limitations of 37 CFR 1.14, as a routine use, to the public if the record was filled in application
 which became abandoned or in which the proceedings were terminated and which application is referenced by either a
 published application, an application open to public inspections or as issued patent.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.